Cerus Endovascularhas received CE Mark approval for the CerusEndo MC 021 microcatheter, which enables physicians to access tortuous neuro vasculature and deliver therapeutic devices to intended targets.
The CerusEndo MC 021 microcatheter, which has already secured the US Food and Drug Administration (FDA) approval, is the company’s first microcatheter to obtain European regulatory approval.
CerusEndo MC 021 microcatheter offers improved proximal support by providing better deliverability and responsiveness in physicians’ hands. It is available in multiple distal flexible profiles.
Cerus Endovascular president Stephen Griffin said: “We remain committed to meeting the ever-increasing needs of the interventional neuroradiologist community, and with that in mind, our team has clearly identified a range of increased performance demands required of a go-to intracranial access microcatheter.
“As a result, we have expanded our key 021 platform so that it can deliver a wider range of devices than it was originally designed for, including stents, braided flow diverters and stentrievers, for treatment of both hemorrhagic and ischemic strokes. In particular, the 021 ensures predictable stability and control when delivering larger and braided devices through the device lumen.”
The company expects to begin the commercial sales of the newly CE-Marked product in the fourth quarter of this year.
In April, Cerus Endovascular secured CE Mark for the Neqstent Coil Assisted Flow Diverter device designed for the treatment of intracranial aneurysms.
Earlier this year, the company raised $19m in a Series B financing from institutional investors to implement the go-to-market strategy and expand the product portfolio.